Card image cap
Biocon Biologics acquires Viatris’ biosimilars business for up to $3.33 billion

Biocon Biologics Ltd, the biologics and insulin subsidiary of Biocon,  said on Sunday that it has entered into a definitive agreement with its US partner Viatris Inc to acquire the latter’s biosimilars business to create a uniquely  integrated global biosimilars enterprise. Viatris will receive consideration of up to $3.33 billion, including cash up to $2.33 billion and compulsorily convertible preference shares (CCPS) in BBL, valued at $1 billion.

Content by Future Medicine

Disclaimer :
The author(s)' thoughts and opinions in this article are their own and do not necessarily reflect DocMode's viewpoint. The article is in no way created or edited by DocMode.

Supported by Koye Pharmaceuticals

Submit a Comment